Lumos Diagnostics Holdings Ltd. (LDX) AI Stock Analysis

• Market Cap: AU$195.44M
• Dividend Yield: N/A
• Average Volume (3M): 5.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.24
• Revenue Growth: 12.96%
• EPS Growth: 40.81%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 797,709,500
• 10 Day Avg. Volume: 3,659,446
• 30 Day Avg. Volume: 5,628,467
• PEG Ratio: 0.04
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.97
• P/FCF Ratio: -1.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): AU$16.10M

• Rating: 49 Neutral
• Price Target: AU$0.26 ▼(-19.06% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is held down primarily by weak financial performance (declining revenue, ongoing losses, leverage, and prior cash outflows). This is partially offset by a constructive earnings-call outlook driven by the PHASE distribution agreement, reimbursement progress, and improving EBITDA/cash flow. Technicals are neutral-to-mildly improving and valuation remains challenged due to unprofitability.

Positive Factors

Material U.S. distribution deal (PHASE)

A guaranteed minimum USD 317M over six years materially derisks U.S. commercialization by providing multi-year revenue visibility. This supports scale-up, justifies upfront commercial investment, and improves contractable cash flow potential versus one-off product sales.

Regulatory progress and reimbursement

A CLIA waiver enables in‑office use and broadens addressable market structurally; paired with a CMS-set reimbursement rate of USD 41.38, this improves unit economics and lowers adoption friction for physician offices, supporting sustained demand and higher-volume adoption if approval is granted.

High margins & improving cash generation

Sustained high gross margins and a return to positive operating cash flow indicate scalable unit economics and improved cash discipline. Nondilutive funding (BARDA/grants) strengthens near-term liquidity and reduces immediate equity dilution while supporting product development and commercialization.

Negative Factors

Declining revenue and ongoing losses

Negative revenue growth and continued adjusted EBITDA losses show the company has not yet achieved profitable scale. Persistent operating losses can erode liquidity, limit reinvestment capacity, and increase reliance on external financing during a multi-year commercial ramp.

High leverage and weak balance sheet

A debt-to-equity ratio above 1 and negative ROE signal constrained financial flexibility. High leverage raises refinancing and interest risks, particularly while unprofitable, and may limit the company’s ability to fund required manufacturing scale‑up or absorb setbacks without dilutive or costly financing.

Execution risk: CLIA waiver dependency & capacity needs

Major U.S. revenue upside depends on FDA granting the CLIA waiver; until then adoption is constrained. Separately, current manufacturing capacity only covers early PHASE demand, requiring near-term capital expenditure to scale—both factors create execution and financing risk during commercialization.

Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model

Company Description

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

How the Company Makes Money

Lumos makes money primarily through (1) sales of diagnostic products and related consumables where it manufactures and/or commercialises tests under its own portfolio, and (2) contract/service revenue from partnering with other organisations to develop, transfer, scale, manufacture, and/or commercialise diagnostic tests. Product revenue is generated when distributors, healthcare providers, laboratories, or other customers purchase finished test kits and, where applicable, repeat-use consumables associated with those tests. Partnership and contract revenue is generated through arrangements that may include development services (fees tied to R&D and assay development work), milestone payments (earned upon achieving agreed technical, regulatory, or commercial objectives), and in some cases ongoing commercial economics such as manufacturing margins, supply agreements, or royalties tied to a partner’s product sales. The company’s earnings can be significantly influenced by the timing and success of regulatory approvals, customer adoption rates, tender or institutional purchasing cycles, and the scale and longevity of partner programs and supply contracts. Specific material partnerships, named products, and the precise mix of revenue by stream are not available in this response and are therefore null.

Lumos Diagnostics Holdings Ltd. Financial Statement Overview

Summary

Financial statements indicate weak fundamentals: declining revenue (-14.8%), ongoing losses (negative net/EBIT margins), high leverage (debt-to-equity 1.13) with negative ROE, and historically negative operating/free cash flow. While gross margin is solid (~63%) and the earnings call notes recent improvement in adjusted EBITDA and operating cash flow, the provided statement scores (IS 35, BS 40, CF 30) still point to elevated financial risk.

Income Statement

Lumos Diagnostics Holdings Ltd. has faced significant challenges in its income statement. The company has experienced a decline in revenue growth, with a negative growth rate of -14.8% in the most recent year. Profitability metrics such as net profit margin and EBIT margin are negative, indicating ongoing losses. The gross profit margin remains relatively stable at around 63%, which is a positive aspect. However, the overall financial performance is weak due to persistent losses and declining revenues.

Balance Sheet

The balance sheet of Lumos Diagnostics Holdings Ltd. shows a high debt-to-equity ratio of 1.13, indicating significant leverage. The return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio stands at around 29.6%, suggesting a moderate level of equity financing. Overall, the balance sheet reflects financial instability with high leverage and negative returns.

Cash Flow

The cash flow statement reveals substantial challenges for Lumos Diagnostics Holdings Ltd. The company has a negative operating cash flow and free cash flow, indicating cash outflows from operations. The free cash flow growth rate is significantly high at 1493.7%, but this is due to a low base effect rather than improved cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow issues. Overall, the cash flow situation is concerning with persistent cash outflows.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	12.33M	12.50M	11.13M	10.54M	11.63M	18.85M
Gross Profit	364.53K	7.91M	7.10M	5.32M	4.46M	8.60M
EBITDA	-9.29M	-4.63M	-5.44M	-4.93M	-25.67M	-10.69M
Net Income	-9.35M	-7.18M	-8.59M	-8.97M	-45.72M	-15.03M
Balance Sheet
Total Assets	21.12M	20.81M	26.84M	25.42M	36.94M	97.99M
Cash, Cash Equivalents and Short-Term Investments	3.00M	1.96M	6.48M	3.02M	7.98M	44.89M
Total Debt	11.85M	6.99M	8.06M	9.79M	7.19M	7.96M
Total Liabilities	15.88M	14.65M	19.73M	15.92M	19.05M	39.71M
Stockholders Equity	5.24M	6.16M	7.11M	9.50M	17.89M	58.28M
Cash Flow
Free Cash Flow	-2.47M	-9.39M	848.00K	-9.79M	-22.39M	-16.77M
Operating Cash Flow	-2.24M	-9.33M	946.00K	-9.64M	-18.04M	-10.89M
Investing Cash Flow	-225.41K	-53.00K	-98.00K	4.31M	-4.36M	-8.33M
Financing Cash Flow	-50.75K	5.28M	2.63M	652.00K	-10.92M	63.27M

Lumos Diagnostics Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LDX, the sentiment is Neutral. The current price of 0.32 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.27, and above the 200-day MA of 0.18, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.62 is Neutral, neither overbought nor oversold. The STOCH value of 10.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:LDX.

Lumos Diagnostics Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LDX	49 Neutral	AU$195.44M	-7.39	-164.12%	―	12.96%	40.81%
RHY	49 Neutral	AU$64.67M	-4.75	-476.27%	―	―	56.42%
MAP	49 Neutral	AU$43.85M	-1.06	-63.04%	―	29.60%	33.00%
BDX	42 Neutral	AU$33.92M	-2.45	-164.22%	―	―	23.85%
GSS	41 Neutral	AU$17.26M	-2.23	-23.93%	―	62.81%	16.37%
IIQ	38 Underperform	AU$46.46M	-3.02	-37.14%	―	2.33%	12.50%

Lumos Diagnostics Holdings Ltd. Corporate Events

Lumos Diagnostics Seeks ASX Quotation for Additional Shares

Lumos Diagnostics Holdings Ltd. has applied for quotation on the ASX of 4,495,817 new ordinary fully paid shares, dated 4 March 2026. The new securities arise from the exercise or conversion of existing options or other convertible securities, modestly expanding the company’s listed share base and potentially enhancing its liquidity in the market.

This additional quotation reflects ongoing capital structuring activities and signals continued engagement with equity markets to support Lumos Diagnostics’ corporate objectives. For existing shareholders and potential investors, the incremental increase in quoted securities may influence trading dynamics, including turnover and market depth for the LDX stock.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Releases 1H FY26 Results Presentation and Hosts Investor Webinar

Lumos Diagnostics has released an investor presentation detailing its first-half FY26 financial results, which were announced on 27 February 2026, and made the materials available to the market. The company is also hosting a webinar for shareholders and potential investors on 3 March 2026 to discuss the results and engage with the investment community, underscoring its efforts to maintain transparency and investor outreach.

The announcement highlights Lumos’ ongoing communication with investors at a time when rapid, point-of-care diagnostics remain strategically important in healthcare. By coupling the publication of its 1H FY26 results presentation with a live investor briefing, Lumos aims to deepen stakeholder understanding of its performance and strategic direction, which may influence market perceptions and support its positioning in the diagnostics sector.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Hits Key U.S. Milestones as FebriDx Push Accelerates

Lumos reported strong momentum in the first half of FY26, underpinned by a six-year exclusive U.S. distribution agreement worth up to US$317 million for FebriDx with PHASE Scientific and the completion and submission of its CLIA waiver clinical study to the FDA. The company also commenced a BARDA-funded paediatric CLIA-waived study, secured 100% Medicare reimbursement coverage across all seven U.S. MAC jurisdictions, and strengthened its cash position with US$2.75 million in non-dilutive grants and a A$5 million loan facility, supporting operations until the anticipated CLIA waiver decision by the end of Q1 2026.

Operationally, Lumos saw FebriDx revenue rise by US$1.4 million over the prior corresponding period and achieved positive operating cash flow of US$0.8 million, reflecting a US$7.1 million improvement. These milestones collectively improve the company’s commercial readiness for broad U.S. rollout of FebriDx, enhance its reimbursement footing, and de-risk its near-term funding needs, positioning it more competitively in the point-of-care diagnostics market ahead of the key FDA CLIA waiver outcome.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics’ Half-Year Loss Widens as Going-Concern Risks Mount

Lumos Diagnostics Holdings Limited reported a 2.9% decline in revenue from ordinary activities to US$6.12 million for the half-year ended 31 December 2025, while its net loss after tax widened 74% to US$4.88 million compared with the prior corresponding period. The company did not declare any dividends, saw net tangible assets per share fall further into negative territory, and its reviewed interim financial statements include an auditor’s note flagging material uncertainty over its ability to continue as a going concern, underscoring heightened financial pressure for shareholders and creditors.

The financial results indicate continued operational and balance-sheet challenges, with rising losses and deteriorating asset backing per share marking a weaker capital position for the group. The going-concern uncertainty cited by the auditors highlights increased risk around Lumos Diagnostics’ future funding and sustainability, which may affect investor confidence and the company’s flexibility to invest in growth or navigate industry competition.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Hits Paediatric Trial Milestone, Unlocks BARDA Funding for FebriDx Expansion

Lumos Diagnostics has achieved a key enrollment milestone in its BARDA-funded paediatric clinical study evaluating the FebriDx rapid test in children aged 2 to 12 years. This milestone completion triggers a US$720,000 payment, bringing total milestone receipts for the study to US$1.92 million out of a potential US$6.2 million tied to 12 predefined project events.

The study is designed to support U.S. regulatory expansion of FebriDx into CLIA-waived settings and paediatric use, building on its current FDA 510(k) clearance for patients aged 12 to 64 years in urgent and emergency care. If successful, the expanded indications and CLIA waiver would substantially increase Lumos’ addressable U.S. market, opening access to hundreds of thousands of additional clinical sites and providing clinicians treating younger children with an additional tool to differentiate bacterial from non-bacterial acute respiratory infections.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Issues New Shares on Employee Option Exercises, Affirms Compliance Ahead of Half-Year Report

Lumos Diagnostics has issued a total of 768,159 fully paid ordinary shares following the exercise and cashless exercise of unquoted employee options, increasing its share capital without a separate disclosure document under Australian Corporations Act provisions. The company confirmed it remains compliant with its continuous disclosure and financial reporting obligations and stated that its forthcoming FY 2026 half-year financial report, due by 27 February 2026, is not expected to contain excluded information, signalling routine capital management and governance processes with no undisclosed material changes for investors at this stage.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Seeks Quotation of Additional 768,159 Shares on ASX

Lumos Diagnostics Holdings Ltd has applied for quotation on the ASX of 768,159 new ordinary fully paid shares, to be issued on 5 February 2026 under its code LDX. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, will modestly expand the company’s share base and provide incremental capital or facilitate incentive arrangements, signalling ongoing corporate activity as Lumos seeks to support its operations and growth within the diagnostics sector.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Issues Cautious Q2 FY26 Financial Presentation

Lumos Diagnostics Holdings Limited has released its Q2 FY26 presentation, outlining financial information prepared primarily in US dollars and reiterating that the material is for informational purposes only and not an offer or recommendation to invest. The company emphasises extensive disclaimers about the accuracy and completeness of the data, the inherent uncertainty of forward-looking statements, the non-IFRS nature of some financial metrics, and the need for investors to undertake their own due diligence and seek professional advice, underscoring a cautious and compliance-focused approach to its market communications.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Boosts FebriDx Sales as It Advances U.S. CLIA Waiver and Secures Full Medicare Reimbursement

Lumos Diagnostics reported unaudited revenue of US$2.7 million for the quarter to 31 December 2025, down 6.9% on the prior corresponding period, as growth in its flagship FebriDx® product and third‑party CorDx combo tests was unable to fully offset the loss of revenue from its discontinued ViraDx® test. Product revenue came in at US$0.5 million and services revenue held steady at US$2.2 million, supported largely by 12 active customer projects, including the Phase 2 Hologic fFN development program and related IP licensing income. FebriDx® sales rose 4.3 times year-on-year, driven primarily by U.S. demand, while Lumos secured full Medicare reimbursement recognition across the United States and initiated a paediatric study that had enrolled 90 patients by the end of December. The company also advanced its bid for a CLIA waiver for FebriDx®, completing FDA‑requested minor updates to user instructions and a supplemental usability assessment, and remains optimistic that the waiver process is progressing in line with expectations. Lumos ended the quarter with US$3.0 million in cash, down US$1.5 million over three months, and reported an operating cash outflow of US$1.0 million, leaving its undrawn A$5.0 million loan facility as an additional liquidity buffer.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Wins Follow-On Contract to Lead FDA-Bound Trial for Aptatek’s PKU Device

Lumos Diagnostics has secured a follow-on contract with New Jersey-based Aptatek Biosciences to manage an Institutional Review Board-approved multi-centre clinical study aimed at obtaining US Food and Drug Administration clearance for PheCheck, an aptamer-based in-home monitoring device for phenylketonuria (PKU). Valued at about US$0.4 million and scheduled to begin in the second quarter of calendar 2026 for roughly six months, the contract expands Lumos’s role beyond product development into full clinical and regulatory support, including study management, data analysis and preparation of the clinical report for FDA submission, and runs in parallel with ongoing product development and verification work; successful clearance could position Lumos for further revenue from test and reader manufacturing, strengthening its presence in the high-value rare disease diagnostics segment as PheCheck, which already holds FDA Breakthrough Device designation, targets a critical unmet need in at-home PKU monitoring.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Issues New Shares on Option Exercises, Confirms Regulatory Compliance

Lumos Diagnostics has issued a total of 5,228,863 new fully paid ordinary shares following the exercise of unquoted options by Lind Global Fund II and a company employee, with the shares issued without a prospectus under relevant Corporations Act provisions. In a cleansing notice to the market, the company confirmed it remains compliant with its continuous disclosure and financial reporting obligations, stated there is no excluded information that must be disclosed ahead of its FY 2026 half-year report due by 27 February 2026, and indicated that the expected draft of that report does not contain undisclosed price-sensitive information, helping to maintain regulatory transparency for investors as its capital base modestly expands.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Seeks ASX Quotation for 5.2 Million New Shares

Lumos Diagnostics Holdings Ltd. has applied to the ASX for quotation of 5,228,863 new ordinary fully paid shares, to be traded under its existing ticker LDX. The issuance of these additional securities, arising from the exercise or conversion of existing instruments, modestly expands the company’s listed share capital and may enhance liquidity for investors while signalling ongoing capital management activity.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

Lumos Diagnostics Showcases FebriDx in Investor Webinar on Reducing Diagnostic Uncertainty

Lumos Diagnostics is hosting an investor and shareholder webinar titled “Reducing Diagnostic Uncertainty” to showcase how its FebriDx rapid diagnostic test supports evidence-based antibiotic stewardship in outpatient and urgent care settings, particularly during the busy cold and flu season. The session will feature real-world insights from WellStreet Urgent Care, where FebriDx has been integrated into high-volume workflows to improve diagnostic clarity, strengthen stewardship practices, and enhance clinical efficiency, underlining the test’s growing clinical adoption and highlighting Lumos’ positioning in the point-of-care diagnostics market; a recording will be available to all registered participants after the event.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.